Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Feb 20;14(1):32.
doi: 10.1038/s41408-024-01000-2.

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar  1 , Ahmad Nanaa  2   3   4 , Ehab Atallah  5 , Rory M Shallis  6 , Sacchi de Camargo Correia Guilherme  7 , Aaron D Goldberg  8 , Antoine N Saliba  3 , Anand Patel  9 , Jan P Bewersdorf  8 , Adam S DuVall  10 , Danielle Bradshaw  10 , Yasmin Abaza  11 , Guru Subramanian Guru Murthy  5 , Neil Palmisiano  12 , Amer M Zeidan  6 , Vamsi Kota  10 , Mark R Litzow  3
Affiliations
Comparative Study

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar et al. Blood Cancer J. .

Abstract

PubMed Disclaimer

Conflict of interest statement

TB served in advisory board for Pfizer, Takeda and Morphosys. AP received research funding from Pfizer, Kronos Bio; Honoraria from AbbVie and Bristol Myers Squibb. ADG received research funding from AbbVie, Aprea, Aptose, AROG, Celularity, Pfizer, and Prelude; Consultancy and Advisory Boards with AbbVie, Astellas, Daiichi Sankyo; Honoraria from Dava Oncology. The other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Co-Mutation Patterns & adverse cytogenetic findings observed in the TP53 Cohort.
This figure illustrates the patterns of co-mutations identified in the TP53 cohort, categorized by treatment arm. Additionally, the data was further stratified based on two groups: the patients who achieved CR/CRi (A) and the primary refractory group (B).
Fig. 2
Fig. 2. Kaplan–Meier survival curves by treatment regimens.
This figure illustrates Kaplan–Meier curves of treatment-naïve mutated TP53 AML patients, stratified by the treatment received—HMA + VEN vs. HMA: A Median Duration of Response. B Event-Free Survival. C Overall Survival.
See this image and copyright information in PMC

References

    1. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549–56. doi: 10.1038/s41591-020-1008-z. - DOI - PMC - PubMed
    1. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K. TP53 Mutations Emerge at Early Phase of Myelodysplastic Syndrome and Are Associated With Complex Chromosomal Abnormalities. Blood. 1995;85:2189–93. doi: 10.1182/blood.V85.8.2189.bloodjournal8582189. - DOI - PubMed
    1. Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97:E232–E5. doi: 10.1002/ajh.26546. - DOI - PubMed
    1. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, et al. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022;12:2516–29. doi: 10.1158/2159-8290.CD-22-0332. - DOI - PMC - PubMed
    1. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. doi: 10.1182/blood-2018-08-868752. - DOI - PMC - PubMed

Publication types

MeSH terms